Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.80 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.80 |
| ▸ | PRKDC | P78527 | 3/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909694 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30002937 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL27008382 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL27129875 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL24680512 | 0.86 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30090547 | 0.86 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL24908855 | 0.86 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30584279 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL26662607 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL26662600 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | PIK3CA 11/4885PIK3CB 4/4885PIK3CD 8/4885 |
| US-20060276470-A1 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | PI4KA, PI4KB, PI4K2B | PIK3CA 16/4885PIK3CB 8/4885PIK3CD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.